Cancer Clinical Trials Information Platform in Hong Kong

  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials

Cancer Site

*in alphabetical order (Last updated on 19/2/2024)


Institution Study Title  
HKU Rectal Adenocarcinoma
(UW21-577)_A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer
Click for Details
CUHK Biliary Tract Cancer

A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Click for Details
CUHK Biliary Tract Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)
Click for Details
CUHK Cancer Pain
(SYM012)A pilot randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus titration of investigators’ choice inadvanced cancer patients in Hong Kong
Click for Details
CUHK Tenosynovial Giant Cell Tumor
(TGC001) A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)
Click for Details
CUHK Endometrial Cancer
(GYE001) A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer – DUO-E
Click for Details

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.